(Q41279638)

29 September 2017

title

Stages IIB and IIIB Hodgkin's disease. Results of combined modality treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

Stages IIB and IIIB Hodgkin's disease.Results of combined modality treatment (English)

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

23 April 2023

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

23 April 2023

author name string

R. Goodman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

P. Mauch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

A. Piro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

D. Rosenthal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

M. Goldstein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

J. Tullis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

S. Hellman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A406981

29 June 2022

language of work or name

English

0 references

publication date

1 July 1977

1 reference

full work available at URL

29 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

23 April 2023

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

23 April 2023

1 reference

29 September 2017

volume

40

1 reference

29 September 2017

issue

1

1 reference

29 September 2017

page(s)

84-89

1 reference

Recent trends in the medical treatment of Hodgkin's disease

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197707%2940%3A1%3C84%3A%3AAID-CNCR2820400116%3E3.0.CO%3B2-D

Mediastinal Hodgkin's disease: a possible danger for intubation anesthesia. Intubation danger in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197707%2940%3A1%3C84%3A%3AAID-CNCR2820400116%3E3.0.CO%3B2-D

Improved survival in Hodgkin's disease

21 January 2018

1

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy

23 April 2023

2

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Second malignancies complicating Hodgkin's disease in remission

23 April 2023

4

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

23 April 2023

5

31

1860

Carbone

1971

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Maximum utilization of the life table method in analyzing survival

23 April 2023

6

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

23 April 2023

7

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

A decade of combination chemotherapy of advanced Hodgkin's disease

23 April 2023

8

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission

23 April 2023

10

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Can pelvic irradiation be omitted in patients with pathologic stages IA and IIA Hodgkin's disease?

23 April 2023

11

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Treatment of Hodgkin's disease using intensive chemotherapy followed by irradiation

23 April 2023

12

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report

23 April 2023

14

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Long term remissions with combined modality therapy for advanced Hodgkin's disease

23 April 2023

16

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

Combination chemotherapy and radiotherapy for Hodgkin's disease

23 April 2023

17

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy

23 April 2023

18

1 reference

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(197707)40:1%3C84::AID-CNCR2820400116%3E3.0.CO;2-D

23 April 2023

Identifiers

10.1002/1097-0142(197707)40:1<84::AID-CNCR2820400116>3.0.CO;2-D

1 reference

29 September 2017

1 reference